Haematologica

Article	Citations
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	185
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	121
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	117
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	111
The first human acute myeloid leukemia genome ever fully sequenced	79
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	72
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	70
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	68
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	67
Acute myeloid leukemia at first relapse: approaching the precipice	66
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	64
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	63
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	61
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	59
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	59
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R	56
Bipartite <i>NUP98</i>::<i>RARA</i>-E412* fusion with a <i>cis</i>-aligned ligand binding domain truncation mutation in atypical acute promyelocytic leukemia	53
P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES	49
P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS	49
Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? – the PRO	48
Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide	48
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review	48
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms	48
Asparaginase-associated hyperammonemia	47
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis	47

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	46
Genetic testing guides therapy in children with refractory cytopenias	43
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	43
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience	43
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	42
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	42
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	40
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia	40
Comprehensive characterization of human bone marrow microenvironment shows age-related changes	40
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	39
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	38
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	36
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	35
Old methods, lasting impact in relapsed/refractory primary mediastinal B-cell lymphoma	34
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	34
Lactoferrin reduces febrile neutropenia in children receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled trial	33
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	32
CD47 expression in acute myeloid leukemia varies according to genotype	32
Next generation sequencing panel for hereditary erythrocytosis in adults with otherwise unexplained erythrocytosis unveils additional genomic variants	32
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	32
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	32
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action	30
CO42 | Dynamic changes after allogeneic stem cell transplantation of extracellular vesicles originated from platelets, endothelial cells and leukocytes after: correlation with acute graft-versus-host	29
Scott syndrome with novel compound heterozygous pathogenic variants in <i>ANO6</i> and reduced thrombin generation	29
The dilemma after chimeric antigen receptor T-cell therapy – to transplant or not?	29
The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat	29
CO05 | Identification of <i>wnk1</i> as a druggable target in <i>TAL1</i>-related T-cell acute lymphoblastic leukemia	28
First-line MAPK inhibition in pediatric histiocytosis: are we ready?	28
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma	28
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	28
<i>Erratum</i> to: “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice”	28
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry	27
Running chromosome analysis in leukemia or not, upfront or later?	27
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study	27
Prehistory of chronic lymphocytic leukemia: clues from the B-cell receptor	27
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase	26
MAPK-kinase mutations and aortic lesions are associated with distribution of circulating monocytes in histiocytosis	26
TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia	26
New bullets in the fight against cancer	26
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients	26
Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of <i>PCM1::JAK2</i> with erythroblastic sarcoma: a case report and literature review	26
P009 | Beyond the Dynamic International Prognostic Scoring System: the role of inflammation in myelofibrosis	25
Intensive induction therapy with FLAG-idarubicin-venetoclax for fit older high-risk patients with acute myeloid leukemia	25
CO58 | Single-cell multi-omics unravels molecular and cellular programs underlying ruxolitinib response in myelofibrosis	25
P059 | <i>WT1</i> reduction after induction therapy predicts outcome in AML patients	25
P005 | ASXL1 variant allele frequency as a modulator of genetic heterogeneity in myelofibrosis	25
CO07 | Single-cell sequencing reveals pathways and perturbations predictive of central nervous system dissemination in B-cell acute lymphoblastic leukemia	25
P023 | SETD2 loss in chronic myeloid leukemia promotes metabolic reprogramming and genomic instability leading to therapeutic resistance and disease progression	25
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report	24
Extracranial internal carotid artery and cerebral infarction in paediatric sickle cell patients	24

Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments	24
Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience	24
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia	24
TNF-α signaling drives myeloid skewing and clonal expansion of stem and progenitor cells in <i>RUNX1</i>-familial platelet disorder	23
Disrupting adaptive proteostasis to overcome proteasome inhibitor resistance	23
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myeloma	23
Chronic lymphocytic leukemia and associated chronic lung diseases	23
Monitoring relapse in post-transplant acute myeloid leukemia requires integrated assessment, with flow cytometry showing the highest efficacy	22
COVID-19 vaccine-induced adverse events predict immunogenicity among recipients of allogeneic hematopoietic stem cell transplantation	22
Safe platelet count for lumbar puncture: are we being overcautious?	22
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)	22
Mutations in the <i>RACGAP1</i> gene cause autosomal recessive congenital dyserythropoietic anemia type III	21
Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation	21
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma	21
How we changed our approach to venous thromboembolism	21
Advocating prudent D-dimer testing: constructive perspectives and comments on ‘How we manage a high D-dimer’	21
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on vire	20
Treatment of lower-risk myelodysplastic syndromes	20
Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoprotein-deficient megakaryocytes	20
Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen	20
Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia	20
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients	20
P23 | DARA-VTD AND ASCT+ LENALIDOMIDE LED TO HIGH COMPLETE REIMISSION AND MINIMAL RESIDUAL DISEASE NEGATIVITY RATES BY NGF: A REAL-WORLD STUDY OF THE TUSCAN MYELOMA NETWORK IN 228 PATIENTS	19
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program	19
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy	19
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KM	19
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	19
Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine	19
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia	19
P61 | IMMUNE EFFECTOR CELL COLITIS DURING TREATMENT WITH AN ANTI-BCMA BISPECIFIC ANTIBODY	19
EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway	19
Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study	19
IgM monoclonal gammopathies of clinical significance: diagnosis and management	19
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia	19
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial	19
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study	19
Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice	18
Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia–lymphoma	18
SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism	18
Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP	18
Getting (T cells) ENGaged	18
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia	18
Aspirin is a life-saving drug for patients with acute myocardial infarction	18
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden	18
LSD1/KDM1A and GFI1B repress endothelial fate and induce hematopoietic fate in induced pluripotent stem cell-derived hemogenic endotheliums	17
Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness	17
COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination Short title: COVID-19 thromboembolism	17
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma	17
Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria	17
von Hippel- Lindau syndrome-related congenital polycythemia and response to belzutifan	17
STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of <i>BCL2</i> and <i>BCLXL</i> following glucocorticoid treatment	17
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma	17
“Bridegroom of blood”- A biblical reference to hemophilia?	17
The French-American-British classification system for acute myeloid leukemia	17
HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: “Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma	17
αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes	17
Bedside treatment algorithm for safe administration of 24-hour high-dose methotrexate in adult acute lymphoblastic leukemia	16
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome	16
Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era	16
More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma	16
Clonal evolution from B-cell acute lymphoblastic leukemia with <i>BCR::ABL1</i> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell	16
An investigation of germline variants of <i>HAVCR2</i> in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population	16
Reply to the Comment on: “Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry”	16
Teclistamab therapy for refractory type 1 cryoglobulinemia Teclistamab in type 1 cryoglobulinemia	16
Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia	16
<i>Ex vivo</i> correction of severe coagulation Factor VII deficiency in patient-derived 3D liver organoids	16
Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemia	15
Comment on "Acute Promyelocytic Leukemia with other <i>RARA</i> rearrangements"	15
LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma	15
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation	15
Duality of Nrf2 in iron-overload cardiomyopathy	15
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma	15
Shaping the future of older pa1ents with Philadelphia-nega1ve lymphoblas1c leukemia	15
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Work	15
CD19/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation	15
LNK/<i>SH2B3</i> as a novel driver in juvenile myelomonocytic leukemia	15
P040 | Metabolic reprogramming and DNA repair plasticity fuel resistance to long-term CHK1/CHK2 inhibition in B-cell acute lymphoblastic leukemia	15
Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study	15
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials	14
P028 | Flow cytometric characterization of myelodysplastic syndrome stem cells: a new prognostic tool	14

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?	14
Introduction. Immunotherapy for childhood malignancies: the future is now	14
The relative importance of platelet integrins in hemostasis, thrombosis and beyond	14
Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria	14
P70 | NOVEL MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE CARE PATHWAY FOR THE EARLY DETECTION OF M PROTEIN RELATED DISEASES	14
Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries	14
The International Prognostic Index: still relevant 30 years later	14
P079 | Assessment by high resolution ultrasound sonography of patients with chronic lymphocytic leukemia treated with BTK inhibitors. Clinical and pharmacoeconomic impact	14
P077 | Clinical profiles and treatment approaches in Italian patients with CLL in clinical practice: findings from a European cross-sectional survey	14
P69 | REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY: AN INTERIM ANALYSIS	14
Type I interferons: leukemia's old foe in the limelight again	14
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.	14
Age-specific mutation profiles and their prognostic implications in pediatric <i>KMT2A</i>-rearranged acute myeloid leukemia	14
<i>Erratum</i> to: “Lower incidence of chronic graft-<i>versus</i>-host disease after ruxolitinib plus extracorporeal photopheresis <i>versus</i> ruxolitinib alone	14
CO11 | BCOR inactivation in B cells initiates CLL-like disease and enables study of disease evolution in a novel mouse model	14
P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE	14
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	14
Entities <i>versus</i> diseases: Myers <i>et al</i>. propose distinct aspects of adult T-cell lymphoma / leukemia.	14
Leon's helmet	14
Diagnostic challenges and proposed classification of myeloid neoplasms with overlapping features of thrombocytosis, ring sideroblasts and concurrent del(5q) and <i>SF3B1</i> mutations	13
Adenosine signaling inhibits erythropoiesis and promotes myeloid differentiation	13
CO28 | NONO shapes multiple myeloma progression through paraspeckle-dependent and independent pathways	13
CCRL2 and who? An important driver in <i>TP53-</i>mutant myeloid leukemias	13
Teclistamab <i>versus</i> B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis	13
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome	13
CO20 | Immune dysregulation in multiple myeloma: uncovering the role of non-malignant B cells	13
More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune	13
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-ce	13
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors	13
PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes	13
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia	13
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy	13
P016 | A novel insight into the role of CCM genes in myeloproliferative neoplasms	13
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding	13
Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade	13
CO32 | ARQ531 targets MAPK–S6K1 signaling and synergizes with lenalidomide in RAS-mutant and wild-type multiple myeloma	13
Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow	13
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options	13
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia	13
Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States	13
Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD-19-directed immunotherapy	13
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?	12
Response to the Comment: “Advocating prudent D-dimer testing: constructive perspectives and comments on “How we manage a high D-dimer”	12
Lipid dysregulation after hematopoietic stem cell transplant	12
P039 | Targeting oncogene-induced senescence in ETV6::RUNX1 pre-leukemic cells	12
Sex differences in progression of kidney disease in sickle cell disease	12
P77 | LIGHT CHAIN DEPOSITION DISEASE: A RARE CAUSE OF RENAL INJURY WITH EMERGING THERAPEUTIC OPTIONS	12
Acute leukemia of ambiguous lineage: the known and the uncertain	12
CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis	12
Haploidentical transplantation in sickle cell disease: toward donor availability for all patients	12
Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma	12
Amyloidogenic light chains impair plasma cell survival	12
The effects of cardio-selective β blockade on diastolic dysfunction in children with sickle cell disease	12
The E3 ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia	12
Von Willebrand disease: classification and epidemiology	12
Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses	12
All patients with AML and <i>FLT3</i>-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO	12
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma	12
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma	12
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study	12
Home time among older adults with acute myeloid leukemia by therapy intensity	12
<i>Erratum</i> to: Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study	12
The landmark contribution by Erik von Willebrand	12
Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide	12
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings	12
Myeloid neoplasms after follicular helper T-cell lymphomas: a real, but limited risk	12
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone	12
Ethnicity in systemic AL amyloidosis may impact risk stratification	11
Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.	11
An unusual case of basophilic meningitis revealing a chronicphase chronic myeloid leukemia: a report after almost three years of follow-up	11
Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early-stage and relapsed multiple myeloma	11
Functional, biochemical, molecular and clinical characterization of antithrombin c.1157T>C (p.Ile386Thr), a recurrent Polish variant with a founder effect	11
Artificial intelligence-based Myelodysplastic Syndromes Score, 2022 classifications, and the Molecular International Prognostic Scoring System: a perfect match	11
Post-CAR-T lymphocytosis in multiple myeloma: too much of a good thing?	11
Arkadia: a new player in hematopoietic stem and progenitor cell development	11
Enhancement of PRMT6 binding to a novel germline <i>GATA1</i> mutation associated with congenital anemia	11
Evaluation of the <i>ATM</i> L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms	11
Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortali	11
Somatic genetic alterations predict hematological progression in GATA2 deficiency	11
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir	11
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax	11
<i>BRCA1/2</i> mutations and <i>de novo</i> hematologic malignancies: true, true and not clearly related	11
Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia	11
Transforming mantle cell lymphoma: the journey across eras	11
Phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup> dependent 1B regulates the hematopoietic stem cells homeostasis via the Wnt/β-catenin signaling	11
Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, <i>TP53</i> alterations and poor prognosis	11
Do it once, but do it right	11
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T	11
Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration	11
Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States	11
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application	11
The double-edged sword of adenosine	11
Body mass index during and early after therapy for pediatric acute lymphoblastic leukemia is associated with obesity in survivors	11
RNA helicase DHX15 exemplifies a unique dependency in acute leukemia	11
Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment	11